{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Arcus Biosciences, Inc.
Arcus Biosciences Hits Day High with 13.97% Surge Amid Market Decline
Arcus Biosciences, Inc. saw a notable increase in its stock price on October 13, 2025, reaching an intraday high. The company has outperformed the S&P 500 recently, despite facing challenges such as low return on equity and negative EBITDA. Its market capitalization is classified as small-cap.
Arcus Biosciences Opens with 8.22% Gain, Contrasting S&P 500's Decline
Arcus Biosciences, Inc. opened with a significant gain amid a broader market decline. Over the past month, the company has shown strong performance, despite facing challenges such as low profitability and a substantial drop in profits. Technical indicators present a mixed outlook for the stock's future.
Arcus Biosciences Hits Day High with Strong 7.27% Intraday Surge
Arcus Biosciences, Inc. has seen a significant intraday increase, contrasting with a slight decline in the S&P 500. Despite recent gains, the company faces long-term challenges, including a decline in one- and three-year performance metrics, low return on equity, and negative EBITDA, indicating ongoing financial struggles.
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge
Arcus Biosciences, Inc. has seen significant short-term gains, with an 8.46% increase today and an 8.71% rise over the past week. However, the company faces long-term challenges, including a year-to-date decline and a notable drop over three years, alongside low profitability and a negative debt-to-equity ratio.
Arcus Biosciences Hits Day High with 9.94% Surge in Strong Intraday Performance
Arcus Biosciences, Inc. saw a notable increase in stock performance on September 30, 2025, reaching an intraday high of USD 13.62. Despite recent gains, the company has faced profitability challenges, with a low return on equity and a negative EBITDA, and a market capitalization of USD 1,218 million.
Arcus Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Arcus Biosciences, Inc. has recently revised its evaluation amid market dynamics, with its stock price showing a slight increase. The company has experienced notable volatility over the past year, with significant fluctuations in stock performance compared to the S&P 500, reflecting both short-term gains and longer-term challenges.
Is Arcus Biosciences, Inc. technically bullish or bearish?
As of September 26, 2025, Arcus Biosciences shows a bullish technical trend with mixed strength indicators, having outperformed the S&P 500 recently but significantly underperformed over the longer term.
Arcus Biosciences Forms Golden Cross, Signaling Potential Bullish Breakout
Arcus Biosciences, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators show a mixed but generally positive outlook, with bullish trends in moving averages and MACD. Despite a challenging year, the stock has shown resilience with notable recent gains and a strong one-month performance.
Is Arcus Biosciences, Inc. technically bullish or bearish?
As of September 26, 2025, Arcus Biosciences, Inc. shows a bullish technical trend with mixed indicator strength, outperforming the S&P 500 recently but having significantly negative long-term returns.
Is Arcus Biosciences, Inc. technically bullish or bearish?
As of September 26, 2025, Arcus Biosciences, Inc. shows a bullish trend despite mixed signals, outperforming the S&P 500 in the short term with returns of 3.63% and 23.70% over the past week and month, but has a year-to-date return of -13.77% compared to the S&P 500's 12.96%.
Is Arcus Biosciences, Inc. technically bullish or bearish?
As of September 11, 2025, Arcus Biosciences, Inc. shows a mildly bullish trend supported by positive MACD indicators and outperformance against the S&P 500 in the short term, but caution is advised due to mixed signals and negative long-term returns.
Is Arcus Biosciences, Inc. overvalued or undervalued?
As of February 28, 2023, Arcus Biosciences, Inc. is considered risky due to overvaluation indicated by negative financial metrics, including a Price to Book Value of 1.99, an EV to Sales ratio of 0.84, a negative ROE of -73.63%, and a poor year-to-date stock performance of -16.45% compared to the S&P 500's 12.22% return.
Is Arcus Biosciences, Inc. overvalued or undervalued?
As of February 28, 2023, Arcus Biosciences, Inc. is considered overvalued and risky due to negative earnings, troubling financial ratios, and a year-to-date stock return of -42.04%, significantly underperforming compared to its peers and the S&P 500.
Is Arcus Biosciences, Inc. technically bullish or bearish?
As of June 9, 2025, the technical trend is mildly bearish, influenced by mixed signals from various indicators, including bearish moving averages and Bollinger Bands, despite some bullish readings on the weekly MACD and OBV.
Who are in the management team of Arcus Biosciences, Inc.?
As of March 2022, the management team of Arcus Biosciences, Inc. includes Dr. Terry Rosen (CEO), Dr. Juan Jaen (President), and several directors including Dr. Yasunori Kaneko and Dr. David Lacey, among others, who oversee the company's strategic direction and operations.
What does Arcus Biosciences, Inc. do?
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy, with a market cap of $921.20 million and recent net sales of $28 million, but a net loss of $112 million. The company does not currently pay dividends and has negative key financial metrics.
How big is Arcus Biosciences, Inc.?
As of Jun 18, Arcus Biosciences, Inc. has a market capitalization of 921.20 million, with net sales of 141.00 million and a net profit of -391.00 million over the latest four quarters. The company reported shareholder's funds of 485.00 million and total assets of 1,150.00 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
